Hereditary Angioedema Therapeutics Market To Reach $8.18 Billion By 2033

Hereditary Angioedema Therapeutics Market Growth & Trends

The global hereditary angioedema therapeutics market size is expected to reach USD 8.18 billion by 2033, registering a CAGR of 10.43% from 2026 to 2033, according to a new report by Grand View Research, Inc. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China’s National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

 Request a free sample copy or view report summary: Hereditary Angioedema Therapeutics Market Report

Hereditary Angioedema Therapeutics Market Report Highlights

• The kallikrein inhibitor segment dominated the market with the largest revenue share of 46.14% in 2025, driven by strong clinical efficacy in reducing the frequency and severity of hereditary angioedema attacks and increasing physician confidence in targeted therapies.

• The on-demand segment dominated the market with the largest revenue share of 60.77% in 2025 due to the critical need for immediate treatment during acute hereditary angioedema attacks.

• The intravenous segment dominated the market, accounting for 54.58% of revenue in 2025, driven by the widespread use of intravenous C1 esterase inhibitor therapies for both acute treatment and prophylaxis in the management of hereditary angioedema.

• North America held the largest hereditary angioedema therapeutics market share of 39.50% in 2025 due to advanced healthcare infrastructure and strong presence of leading biopharmaceutical companies.

Hereditary Angioedema Therapeutics Market Segmentation

Grand View Research has segmented the global hereditary angioedema therapeutics market on the basis of treatment, end use, route of administration, and region:

Hereditary Angioedema Therapeutics Treatment Outlook (Revenue, USD Million, 2021 - 2033)

• C1-Inhibitor Concentrates

• Bradykinin B2 Receptor Antagonist

• Kallikrein Inhibitor

• Others

Hereditary Angioedema Therapeutics End use Outlook (Revenue, USD Million, 2021 - 2033)

• Prophylaxis

• On-demand

Hereditary Angioedema Therapeutics Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

• Intravenous

• Subcutaneous

• Oral

Hereditary Angioedema Therapeutics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Hereditary Angioedema Therapeutics Market

• BioCryst Pharmaceuticals, Inc.

• Ionis Pharmaceuticals

• CSL

• Attune Pharmaceuticals

• Adverum Biotechnologies, Inc.

• KalVista Pharmaceuticals, Inc.

• Takeda Pharmaceutical Company Limited

• Pharming

• Sanofi

• Pharvaris B.V.

• Arrowhead Pharmaceuticals, Inc.